ArticleScientific reports2025
Evaluating the effect of 0.125% atropine on foveal microvasculature using optical coherence tomography angiography.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Combination therapy for myopia control using defocus incorporated multiple segments spectacles in children refractory to higher-dose atropine.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Short-term effects of atropine on the retina and choroid in young adults.Eye and vision (London, England) · 2026Article
- Early identification of the efficacy of 0.125% atropine treatment for children with Myopia: A prospective pilot study.PloS one · 2025Article
- Retinal vasculature changes after 0.125% atropine treatment in children with myopia measured using optical coherence tomography angiography: A pilot study.Taiwan journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated alterations in the foveal microvasculature following the administration of 0.125% atropine in myopic children. In this prospective study, 63 eyes from 36 individuals aged 5-18 years with myopia were administered 0.125% atropine for myopia control. After administration, foveal microvascular parameters such as the area and perimeter of the foveal avascular zone (FAZ), the acircularity index (AI) of FAZ, and foveal vessel density were evaluated longitudinally. The effect of atropine on foveal microvasculature was analyzed using a linear mixed model. One month after atropine application, the area and perimeter of FAZ significantly decreased (p = 0.014 and 0.041). A significant decrease in vessel density within the 300-µm wide annulus around FAZ and an increase in the AI of the FAZ were observed in the initial 3-month period (p = 0.035 and p = 0.047, respectively). However, changes in the FAZ area, perimeter, AI and foveal vessel density throughout the follow-up were not significant. These findings suggest that 0.125% atropine may induce transient changes in FAZ size and foveal vessel density, but its overall safety in managing myopia is supported by the stability of foveal parameters over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.